Market Brief Advisory Connect Pricing

Market entry decisions for health products.

Put in your product and target market — pharma, medtech, diagnostics, or digital health — and get your market entry answer. Regulatory approval, procurement, pricing, and available funding. Cited to actual government sources. Ready in minutes.

90 markets. 50 US states and 40+ international. The same framework that maps Texas Medicaid maps Vietnam or Saudi Arabia.

90
markets covered
Cited
to primary sources
$20–40K
replaced
Minutes,
not months
vantrohealth.com · market-brief
MARKET BRIEF
1 of 2
Market Brief
Compare Markets

Here's what that looks like.

Get your market entry answer.

Regulatory approval, procurement, pricing, and funding — across 90 markets.

📋 Market Brief
Brazil Market Overview
Regulatory Path ANVISA Reliance
Procurement Private / Public Hybrid
Pricing $280–$350 USD
✓ Recommended
⚖️ Compare Markets
🇲🇽 Mexico vs. 🇮🇩 Indonesia
Mexico Indonesia
Approval Time 6 months 12 months
Pricing Limits No Cap Price Controls
Funding High Potential Limited Grants
🏆 Top 5 Markets
1Brazil
2Saudi Arabia
3Mexico
4Vietnam
5Poland
🎯 Scenario Planner
Regulatory SpeedFast
Pricing CapLow
Funding AvailabilityHigh
Projected Outcomes
🗺️ GVD Framework
Government Alignment
Value Assessment
Distribution Strategy
Analysis →
🔍 Regulatory Tracker
ANVISA ✓ Submission
FDA ⏳ Pending
EMA ✗ Delayed
90 Markets Covered
Primary Gov't Sources Only
Minutes, Not Months
Market signals

What's changing — and what it means for you

Select your product type to see how each signal affects your market entry.

🇮🇳 India High impact

Semaglutide set to drop to ~$14/month as 40+ manufacturers enter the market.

India's CDSCO fast-track has opened to 40+ domestic GLP-1 manufacturers. Reference pricing is expected to create a new floor across emerging markets.

CDSCO · Apr 2026
🇳🇬 Nigeria Procurement open

GAVI and UNFPA expanding maternal health procurement as Nigeria increases BHCPF allocations.

Nigeria's 2026 BHCPF allocation rose 22%, unlocking new tender rounds. NAFDAC is offering a 90-day fast-track for maternal health product registration.

NAFDAC · Mar 2026
🇨🇳 China Policy shift

VBP procurement rebalancing creates preferential access for domestic manufacturers across health product categories.

NMPA's latest VBP guidance moves imported products to secondary tender rounds. Private hospital networks remain the primary commercial channel for foreign entries.

NMPA · Feb 2026
Set up your tracker — curated to your product, to your inbox, at your desired frequency →

Vietnam — Enter via Ministry of Health tender pathway. Biosimilar pricing window open Q3 2025. Recommended.

🇻🇳
Vietnam · Biosimilar Insulin
WHO PQ held
WHO PQ held Hybrid Procurement
Verified Feb 2026
Entry Profile

WHO PQ held products qualify for DAV expedited review via reliance pathway, compressing registration to 6–9 months. The Ministry of Health has identified insulin access as a national health priority under the National Diabetes Programme. Public procurement through hospital tenders accounts for 60% of volume — private pharmacy channel growing rapidly in urban centres.

Market Context
Disease Burden
5.3M
people with Type 2 Diabetes — 5.4% of population
↑ 7.2M by 2030
IDF Diabetes Atlas 2023
Market Size
$180M
insulin market, growing 12% annually
↑ 12% YoY
IQVIA 2024
Demographics
98M
population · $198 per capita health spend
40M urban middle class
World Bank 2023
Entry Dimensions
Regulatory Ready
Timeline Ready
Procurement Ready
Pricing Moderate
Local partner Moderate
Tax & customs Ready
Key Numbers
6–9 mo
DAV timeline
60/40
Public / Private
0%
Import duty
5%
VAT
Competitor Landscape
Competitor
Channel
Position
Threat
Novo Nordisk / Sanofi
Dominant in MoH hospital tenders. WHO PQ required to compete in public channel.
Both
Dominant
High
Biocon / Dr. Reddy's
Filing WHO PQ — will compress public channel pricing within 18 months.
Public
Emerging
Medium
Vietnam National Diabetes Programme
Government priority — registered suppliers get preferred tender access and formulary listing.
Public
Active
Opportunity
Risk Flags & Opportunities
Price ceiling on essential medicines Local agent mandatory Indian biosimilar competition accelerating WHO PQ fast-tracks DAV review National diabetes priority status 0% import duty
Data Sources
Sample brief. Generate your own — calibrated to your product.
What does this mean for your product? →

Used by market access and BD teams at biotech, specialty pharma, and medtech companies evaluating international expansion.

Generate your brief. It takes 2 minutes. →
Every claim traced to a named source
National Regulatory Authorities
CDSCO NAFDAC SAHPRA PPB Kenya BPOM FDA Philippines EMA MHRA DAV Vietnam TGA SFDA Saudi Arabia MOHAP UAE EFDA Ethiopia FDB Ghana & others
Multilateral & Institutional
WHO World Bank UNICEF Supply Division Global Fund GAVI WHO Collaborating Centres Africa CDC ASEAN Secretariat UNDP & others
CDSCO India· NAFDAC Nigeria· SAHPRA South Africa· PPB Kenya· BPOM Indonesia· FDA Philippines· EMA· MHRA· DAV Vietnam· TGA Australia· World Bank· UNICEF Supply Division· Global Fund· GAVI· WHO Collaborating Centres· Africa CDC· ASEAN Secretariat· UNDP· IDF Diabetes Atlas· IQVIA· SFDA Saudi Arabia· MOHAP UAE· EFDA Ethiopia· FDB Ghana· CDSCO India· NAFDAC Nigeria· SAHPRA South Africa· PPB Kenya· BPOM Indonesia· FDA Philippines· EMA· MHRA· DAV Vietnam· TGA Australia· World Bank· UNICEF Supply Division· Global Fund· GAVI· WHO Collaborating Centres· Africa CDC· ASEAN Secretariat· UNDP· IDF Diabetes Atlas· IQVIA· SFDA Saudi Arabia· MOHAP UAE· EFDA Ethiopia· FDB Ghana·
What's in a Market Brief

Everything your team needs to make the call.

01
Regulatory Pathway

Approval complexity, reliance pathway availability, and authority requirements calibrated to your existing clearances — such as CE Mark, 510(k), TGA, or WHO PQ.

02
Timeline Estimate

Realistic months from submission to commercial clearance, including known authority bottlenecks and distributor onboarding lead times.

03
Procurement Structure

Public vs. private purchasing split, tender cycle cadence, and donor channel relevance — UNICEF, Gavi, Global Fund, and USAID.

04
Pricing & Reimbursement

Whether MoH sets reference or ceiling prices, reimbursement linkage signals, and commercial pricing flexibility in each channel.

05
Local Partner Requirements

Whether a local entity or distributor is legally required, entity type rules, and onboarding lead time for commercial operations.

06
Tax & Customs Exposure

Import duty rates, VAT/GST, medical device exemptions, and landed cost impact on margin and competitive pricing.

Read our full methodology →
Market Finder

Top 5 markets for your product

Enter your product type and existing clearances. Vantro ranks your top 5 markets by ease of entry: regulatory readiness, market size, and time to first sale.

🌍

Your top 5 markets will appear here

Know before you commit.

Market entry decisions used to cost $20,000 to $40,000 per market and take months. Vantro gives your team the same structured intelligence in minutes, cited to primary sources, calibrated to your product.

01
60–120h
typical per-market assessment
Move faster
Based on practitioner research, market entry assessments typically take 60–120 hours per market. Vantro compresses that to hours — accelerating decisions by weeks, sometimes months.
02
more markets, same time
Do more with less
Evaluate 5x more markets in the same time, without adding headcount or consultant retainers.
03
20+
national regulatory authorities
Decide with confidence
Every data point sourced and cited — drawn from the World Bank, UNICEF Supply Division, and 20+ national regulatory authorities. No guesswork, no black-box scoring.
Get in touch

Working on a global expansion?

Tell us about your product and where you're headed.

Pricing

Start free. Pay per insight.

Your first 3 Market Briefs are free. Buy individual briefs when you need them. Subscribe when you're actively managing a market pipeline.

Free
$0
no card required
3 Market Briefs All 6 dimensions Risk flags No PDF export
Market Brief
$39
per brief
Full 6 dimensions Key numbers + sources Risk flags + opportunities Donor channels PDF export
Pro
Most popular
$149
per month
Unlimited briefs Compare markets Role Lens Regulatory Tracker Change alerts 3 team seats Early Connect access
Enterprise
$499
per month · $399 annually
Everything in Pro GVD Framework Builder Pricing Scenario Planner 5 team seats 1hr Advisory/month
Advisory
Custom
tailored engagement
Market entry strategy + board deck Regulatory pathway analysis Product localisation In-country partner introductions